VCN-11 is an oncolytic adenovirus which expresses hyaluronidase PH20 and is also protected from neutralizing anti-adenovirus antibodies to reach systemically multiple metastases and allowing to spread better within tumors by including ABD technology
The ABD technology protects adenoviruses from pre-existing neutralizing antibodies when delivered systemically. The efficacy of adenoviruses used as vaccines, gene therapy vectors and oncolytic viruses is often limited by the previous exposure of adenovirus in humans that leads to the development of neutralizing antibodies that inactivate adenoviruses when given intravenously. Avoiding neutralizing antibodies is necessary to reach multiple metastasis and achieve efficacious cancer treatment. An albumin-binding domain (ABD) was inserted in the adenovirus capsid in a way that when the virus is the blood, naturally occurring albumin can bind to the ABD-adenovirus and protect it from neutralizing anti-adenovirus antibodies. Scientists have recently shown that unmodified adenoviruses are completely neutralized in pre-immunized mice, whereas ABD-adenovirus can efficiently transduce tumors, show anti-tumor activity and generate immune responses to expressed proteins
Developed by Web4Bio